BioStem Technologies (OTCMKTS:BSEM) Shares Down 2.9% – What’s Next?

Posted by Scott Moore on Jul 1st, 2026

BioStem Technologies, Inc. (OTCMKTS:BSEM – Get Free Report) was down 2.9% during trading on Monday . The stock traded as low as $3.39 and last traded at $3.48. 24,258 shares were traded during mid-day trading, a decline of 49% from the average daily volume of 47,737 shares. The stock had previously closed at $3.5850.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on the company. Zacks Research raised BioStem Technologies to a “hold” rating in a research report on Wednesday, March 18th. HC Wainwright started coverage on shares of BioStem Technologies in a research note on Wednesday, May 6th. They set a “buy” rating and a $9.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $9.00.

View Our Latest Report on BioStem Technologies

BioStem Technologies Stock Down 2.4%

The stock has a fifty day simple moving average of $4.15 and a 200 day simple moving average of $4.76. The firm has a market capitalization of $57.41 million, a P/E ratio of -2.89 and a beta of 0.03.

BioStem Technologies (OTCMKTS:BSEM – Get Free Report) last released its quarterly earnings data on Thursday, May 14th. The company reported ($0.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.24). The firm had revenue of $6.14 million during the quarter, compared to analysts’ expectations of $5.70 million. Research analysts anticipate that BioStem Technologies, Inc. will post -1.95 earnings per share for the current fiscal year.

BioStem Technologies Company Profile

(Get Free Report)

BioStem Technologies, Inc, a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases. The company is also engages in the repackaging and distribution of active pharmaceutical ingredients and other pharmaceutical compounding supplies; and develops and markets nutraceutical products under the Dr.